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Opinion statement
Nontuberculous mycobacteria (NTM) are found in approximately 10 % of cystic fibrosis
(CF) patients, but only a portion will develop NTM disease. The management of CF lung
disease should be optimized, including antibiotic therapy targeted to the individual’s
usual airway bacteria, prior to considering treatment for NTM lung disease. Those who
meet criteria for NTM lung disease may not necessarily require treatment and could be
monitored expectantly if symptoms and radiographic findings are minimal. However, the
presence of Mycobacterium abscessus complex (MABSC), severe lung disease, and/or
anticipated lung transplant should prompt NTM therapy initiation. For CF patients with
Mycobacterium avium complex (MAC), recommended treatment includes triple antibiotic
therapy with a macrolide, rifampin, and ethambutol. Azithromycin is generally our
preferred macrolide in CF as it is better tolerated and has fewer drug-drug interactions.
MABSC treatment is more complex and requires an induction phase (oral macrolide and
two IV agents including amikacin) as well as a maintenance phase (nebulized amikacin and
two to three oral antibiotics including a macrolide). The induction phase may range from one
to three months (depending on infection severity, treatment response, and medication
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tolerability). For both MAC and MABSC, treatment duration is extended 1-year post-culture
conversion. However, in patients who do not achieve culture negative status but tolerate
therapy, we consider ongoing treatment for mycobacterial suppression and prevention of
disease progression.
Introduction
Cystic fibrosis (CF) is the most common potentially le-
thal autosomal recessive disease in Caucasians, found in
approximately one in 3000 individuals [1]. While the
incidence of CF is lower in other groups, it is known to
affect multiple ethnicities [1, 2]. CF results from a muta-
tion in the cystic fibrosis transmembrane conductance
regulator (CFTR) gene, which encodes a cell-surface chlo-
ride ion channel [3]. Reduced CFTR activity leads to
impaired chloride ion secretion and viscous secretions,
which can block ducts and lumens in various organs [3].
CF is a systemic disease primarily characterized by in-
volvement of respiratory, gastrointestinal, and the male
reproductive tracts [3]. However, most of the morbidity
and mortality arises from CF lung disease [4, 5]. In the
setting of CF, thick airway secretions lead to impaired
mucociliary clearance, which predisposes to bacterial col-
onization and infection [6]. Recurrent cycles of airway
infections and chronic inflammation eventually lead to
permanent lung damage known as bronchiectasis.
Given the significant burden of pulmonary in-
fection, a critical aspect of CF management revolves
around understanding the microbiology of CF
lungs in order to prevent and treat infections effec-
tively. The CF lung microbiome is diverse and the
spectrum of microbes isolated from CF lungs has
increased in the last couple of decades, partly due
to laboratory advances [6, 7]. Among these,
nontuberculous mycobacteria (NTM) have emerged
as noteworthy pathogens in CF that warrant special
attention.
NTM epidemiology
NTM prevalence and incidence in CF
Reported NTM prevalence in CF ranges from 3 [8•] to 23 % [9]; all studies
defined this as a minimum of one positive respiratory culture, but the studies
are limited by their retrospective design [8•, 9–19]. The largest studies with
3805, 10,527, and 13,593 patients reported an NTM prevalence of 5 [10], 20
[11], and 3 % [8•], respectively (Table1). Overall, the estimated NTM preva-
lence in CF is approximately 9 % [8•, 9–19].
Actual NTM disease prevalence, as defined by the American Thoracic
Society (ATS) criteria [20], is somewhat unclear. Reported NTM disease
prevalence in CF ranges from 4 [12] to 14 % [14] (Table 1). However, this
may not be a true representation, as studies differed in NTM disease definition
(i.e., some used the 1997 ATS criteria which required three positive respiratory
cultures) [21] and none considered radiographic findings.
Geographic variation in NTM prevalence in CF exists within and be-
tween countries [10, 12, 16]. This may be due to differences in screening,
laboratory techniques, or local NTM subtype prevalence in the environ-
ment [16, 22]. NTM incidence in CF appears to be rising in some centers
[14, 17]; hypotheses for this include greater surveillance, better diagnostic
techniques, and/or shifts in the lung microbiome due to more widespread
antibiotic use.
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NTM subtypes
Of the over 150 identified NTM species, only a few have been reported to cause
pulmonary disease [20]. Themajority (95%) of NTM isolated fromCF patients
are Mycobacterium avium complex (MAC) (M. intracellulare and four M. avium
subspecies) and M. abscessus complex (MABSC) (subspecies abscessus,
massiliense, and bolletii) [9, 12, 16, 19]. MAC is generally the most common
(representing 75% of NTM infections in CF), withMABSC accounting for most
of the remainder [16].M. abscessus ssp. abscessus andM. abscessus ssp. massiliense
comprise the majority of MABSC in CF [23]. Less commonly isolated species in
CF areM. kansasii,M. fortuitum, andM. gordonae, among others [9, 12]. Multiple
NTM species may be present simultaneously or over time [12, 14, 17].
The proportion of NTM subtypes within a CF population appears to
have geographic variation, with MABSC and non-MAC species appearing
more common in Europe and Israel (Fig. 1) [9, 10, 15, 16, 24]. Fur-
thermore, there has been an increase in MABSC reported in several
centers [12, 16, 19], possibly due to improvements in MABSC identifi-
cation techniques (16S ribosomal RNA is better at distinguishing MAC
from MABSC), increased environmental MABSC, and/or patient-to-
patient transmission (although uncommon) [25, 26, 27•].
Transmission
It was previously believed that NTM pulmonary infection developed exclusively
in individuals following environmental acquisition, as mycobacteria, is ubiq-
uitous in soil and water [28]. However, an outbreak of M. abscesses ssp
Table 1. Prevalence of NTM positive cultures and NTM lung disease in studies performed since the year 2000









France 2000–2001 385 8 (31) - 19
Israel 2000–2003 186 23 (42) - 9
USA 2000–2007 829 20 (166) 14 (38)a 14
Scandinavia 2000–2012 1411 11 (157) 9 (125)b 17
USA 2003–2004 986 13 (128) 4 (38)c 16
France 2004–2005 1582 7 (104) 4 (57)d 12
USA 2011–2012 5403 4 (191) - 15
USA 2010–2011 10527 14 (1384) - 11
United Kingdom 2013–2014 3805 5 (190) - 10
Europe 2015–2016 13593 3 (374) - 8
*Studies used microbiologic criteria alone to define NTM lung disease
aNTM lung disease definition was based on 3 or more positive cultures out of 271 individuals with longitudinal data
bNTM lung disease definition was based on 2 or more positive cultures out of all 1411 individuals tested for NTM
cNTM lung disease definition was based on 2 or more positive cultures out of all 986 individuals tested for NTM
dNTM lung disease definition was based on 2 or more positive cultures out of all 1582 individuals tested for NTM
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massielensewas first documented at a CF clinic in Seattle, Washington, involving
five patients. The index case was smear positive and had recently transitioned
from another CF center; isolates from the four outbreak cases were genetically
identical and there was overlap with patient visits [25]. Subsequently, there
have been reports of NTM spread in England and Hawaii [25, 26, 27•]. The
largest outbreak occurred in England, where 11 of 31 patients with MABSC had
a shared strain of M. abscessus ssp massiliense with similar antibiotic resistance
patterns despite a lack of exposure to the same antibiotics [26]. Interestingly,
two of these outbreaks involved M. abscessus ssp. massiliense [25, 26]; although
other NTM strains are also likely transmissible between humans, this has not
been documented in the CF literature to date. The potential for direct or indirect
human-to-human transmission underscores the importance of following strict
infection control protocols for prevention [29].
Clinical outcomes of NTM in CF
In the CF population, NTM impact on health outcomes is variable. While MAC
andMABSC are themost frequently isolated NTMs in CF, they are also themost
clinically significant [9, 12, 15, 16, 30]. However, NTM growth can be transient,
and even when persistent, active disease may not develop.
MABSC is more likely to cause invasive NTM lung disease (50 to 80 % of
those with positive sputum) compared to MAC (less than half of those with
positive sputum) [9, 12, 16, 17, 31, 32].
MABSC also accelerates lung function decline in CF patients compared to
uninfected CF controls [14, 32, 33]. In CF, a common measure of lung disease
severity is percent-predicted forced expiratory volume in one second (FEV1), with
lower values indicating more advanced lung disease. In one study, those with
MABSC had a greater rate of FEV1 % predicted decline than other organisms,
Fig. 1. Prevalence of NTM subtypes in CF from different regions of the world.
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including Pseudomonas aeruginosa and Burkholderia cepacia [33]. However, no lung
function decline was noted in patients growingMAC [14]. Similarly, a large study
found no significant effect of NTM infection on lung function decline, although
analyses were not based on different NTM subtypes [16]. Lastly, CF patients with
MABSC are more likely to require transplant or die despite adequate treatment as
reported in a recent study [33].
While some NTM play a role in lung disease progression over time, it
does not appear to be through more frequent CF pulmonary exacerba-
tions (PEx) [34, 35]. It remains unclear if NTM is merely a marker of
worsening lung disease or a causative factor for lung function decline.
However, NTM clearance with treatment has been shown to slow the
rate of lung function decline [33].
NTM impact on lung transplant outcomes in CF also varies [36].
Generally, those with pre-transplant MABSC are more likely to develop
post-transplant invasive MABSC disease, particularly if they are smear-
positive [37–40]. Post-transplant MABSC causes significant morbidity,
but deaths attributable to MABSC are relatively uncommon in CF and
non-CF lung transplant recipients [37–41]. In contrast, post-transplant
MAC lung disease is much less frequent, generally lung limited, and has
high cure rates [37, 38]. All CF patients should be screened for NTM
pre-transplant and, if present, started on treatment prior to transplant
listing [42]. Progressive pulmonary or extra-pulmonary NTM disease
despite appropriate therapy or treatment intolerance is considered a
transplant contraindication [42].
NTM risk factors
Within the CF population, multiple potential risk factors for NTM pulmo-
nary infection have been investigated; while some are consistent between
studies, the majority of factors demonstrate inconsistent associations.
Clinical characteristics, including baseline lung function, have generally
not been linked to NTM risk in CF [8•, 15–17, 43]. The most consistently
identified NTM association is Aspergillus fumigatus co-infection [14, 16, 24,
31, 44]. Those with allergic bronchopulmonary aspergillosis (ABPA) also
had higher rates of NTM in many large studies [8•, 15, 18, 24], but not in
all [45, 46]. Other microorganisms do not appear to be associated with
increased NTM risk [8•, 9, 14, 15, 24]. Younger age, pancreatic insufficien-
cy, and lower baseline lung function are more common with MABSC
compared to MAC in some studies [12, 14, 15, 30, 32, 46].
With increased macrolide use to reduce CF PEx and the parallel
increase in NTM prevalence, there is concern that this practice could
predispose to active NTM pulmonary disease. A proposed mechanism is
macrolide-mediated impairment in macrophage function, leading to re-
duced intracellular bacterial killing [46]. However, results from existing
evidence are mixed with some studies showing an increased risk of NTM
[9, 45], and more recent studies demonstrating no or decreased NTM
risk with chronic macrolide use [8•, 15, 31, 47]. The influence of
macrolides on NTM risk is inconclusive, and macrolides should still be
considered if indicated. Regarding other medications, a recent study
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found that several inhaled medications were associated with increased
NTM risk [8•]. This has not been validated in other studies nor inves-
tigated prospectively. Interestingly, neither inhaled nor oral corticoste-
roids were associated with a higher likelihood of NTM infection in
several large studies [8•, 17, 18, 43, 46].
NTM diagnosis
NTM culture identification
When clinical suspicion exists, patients should collect expectorated sputum
samples on three consecutive mornings to increase yield [20, 48•]. Induced
sputum samplesmay be obtained in subjects unable to readily produce sputum
[20, 48•]. When both expectorated/induced sputum samples are non-
diagnostic or negative but a high index of suspicion for NTM lung disease
remains, bronchoscopy should be pursued for bronchoalveolar lavage [20,
48•]. Transbronchial biopsies are not routinely recommended in CF patients
and should particularly be avoided in those with severe bronchiectatic changes
due to higher pneumothorax risk [48•]. Cough swabs, induced sputum sam-
ples, and bronchoscopy are not required as part of routine surveillance in
individuals unable to expectorate spontaneously [48•]. Routine NTM surveil-
lance should be performed at least annually [48•].
Specimens should be processed within 24 h and require decontamination to
prevent other bacterial overgrowth and to facilitate NTM detection [20]. Addi-
tional decontamination is needed if Gram-negative bacteria persist, a more
prevalent problem in CF [48•, 49]. Respiratory specimens should be incubated
on both liquid media (which improves mycobacterial yield) and solid media
(which allows for growth rate quantification and detection of multiple simul-
taneous NTM strains) [20].
Due to varying clinical implications, all NTM isolates should be identified at
the species level (with the exception of MAC) and the sub-species level in the
case ofMABSC [20, 48•]. Initial mycobacterial identificationmay occur by acid-
fast bacilli detection with Ziehl-Neelsen stain (but sensitivity varies based on
infectious burden). NTM cultures can take anywhere from 7 days (as with
MABSC,M. fortuitum, and M. chelonae) to 12 weeks to grow [20].
Standard laboratory practice for NTM speciation entails either high-
performance liquid chromatography (HPLC) or molecular methods, which
are generally preferred [20, 48•, 50, 51]. Molecular NTM genotyping
options include commercially available DNA probes, PCR product-
restriction enzyme analysis (PRA), or 16S ribosomal RNA sequencing
[20, 48•]. Commercially available NTM-specific DNA probe assays and
PRA testing have high sensitivity and specificity [20, 48•], but the former
is costly and only available for a few NTM types and the latter is not
widely available [20]. NTM-specific 16S ribosomal RNA sequencing has
high sensitivity, superior specificity, provides better discrimination among
rapid growers, and is widely available [20, 48•]. MABSC sub-speciation is
done by multi-locus sequence typing of hsp65, rpoB, and secA genes, a
recently validated technique with fair accuracy [52, 53]. Antibiotic suscep-
tibility profiles can provide a clue to the MABSC subspecies (i.e., macrolide
sensitivity is suggestive of M. abscessus ssp. massiliense); however, confirma-
tory testing is required [48•].
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NTM lung disease
A diagnosis of NTM pulmonary disease must meet both clinical and microbi-
ologic criteria as outlined by ATS guidelines, with exclusion of other etiologies
[20]. Clinical criteria include persistent pulmonary symptoms and radiographic
changes (nodular and/or cavitary opacities on radiograph or bronchiectasis
with nodules on CT scan), and microbiologic criteria require persistent growth
of NTM in respiratory specimens [20]. However, this definition is problematic
in CF and poses a challenge in the accurate diagnosis of NTM lung disease.
Individuals with CF tend to have chronic productive cough, shortness of breath,
and weight loss which can fluctuate and progress, making it difficult to distin-
guish the natural course of CF from evolving NTM lung disease. Furthermore,
CF is characterized by bronchiectatic changes, nodularity frommucus plugging,
and has a predilection for the upper and mid lung zones. Consequently, using
the standard diagnostic criteria for NTM lung disease can lead to over-diagnosis
of disease in CF, and potentially, over-treatment and unnecessary exposure to
antibiotics. Unfortunately, there are no CF-specific criteria for the diagnosis of
NTM lung disease that would address these potential issues.
CF clinicians must use their judgment to decide if the above-mentioned respi-
ratory symptoms and radiographic features have progressed from baseline and are
due to NTM [48•]. A key part of this process entails reviewing the patient’s overall
CF disease status and optimizing management of CF lung disease and comorbid-
ities that could affect respiratory status (including malnutrition, CF-related diabe-
tes, and asthma) [48•]. It is generally recommended to treat PEx caused by more
typical pathogens (e.g., Pseudomonas spp.) to see if the patient returns to baseline,
prior to proceeding with more involved diagnostic tests and treatments for NTM
[48•].
NTM treatment and outcomes
Treatment indications
Individuals who are NTM culture positive but who do not meet ATS criteria for
disease should be followed closely [48•]. Everyone meeting criteria for NTM
lung disease should be considered for therapy; however, treatment decisions
should be individualized [48•, 54]. Itmay be reasonable tomonitor individuals
with mild CF lung disease, MAC lung disease with mild symptoms and radio-
graphic changes, or a high probably of drug intolerance or drug interactions
[54]. Conversely, CF patients withMABSC and/or severe CF lung disease should
generally be treated in the absence of contraindications [54].
Treatment challenges
NTM lung disease treatment is challenging due to long, complicated, and
difficult to tolerate antibiotic regimens [54, 55]. Furthermore, in vitro antibiotic
susceptibility and in vivo response may not correlate [54, 56, 57]. This may be
partly due to NTM biofilm formation, which has only more recently been
recognized in the lungs and appears to be limited to a few species (including
MAC and MABSC) [57, 58]. Treating NTM in CF is associated with additional
difficulties. Achieving therapeutic antibiotic concentrations is a challenge due to
the higher volume of distribution of antibiotics, increased renal clearance, and
possibly decreased gastrointestinal absorption [54, 56]. Increased macrolide
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exposure in CF patients may lead to greater macrolide resistance [53]. Lastly,
treatment tolerance and efficacy may be influenced by interactions with other
chronic medications.
MAC treatment
Standard MAC treatment consists of a macrolide (azithromycin 250 mg or
clarithromycin 1000 mg once daily), rifampin 10 mg/kg daily up to 600 mg, and
ethambutol 15 mg/kg daily [20, 48•]. Treatment duration is for 1 year following
culture conversion (when respiratory specimen culture first becomes negative) [20,
48•]. It is important to note that the culture conversionmust be sustained on serial
repeats and should there be even one positive culture, the clock would need to be
reset on treatment duration [20, 48•]. Azithromycin is generally the preferred
macrolide (despite there being a lack of evidence to suggest that it is superior to
clarithromycin), since it is better tolerated, has fewer drug-drug interactions, and
has the added benefit of reducing CF PEx through an anti-inflammatory mecha-
nism [20, 48•]. Based on ATS guidelines, intermittent dosing is considered accept-
able in nodular NTM lung disease, but it is not advised in patients with CF
(regardless of severity) as intermittent dosing is less likely to achieve therapeutic
drug levels in this group [20, 48•]. A parenteral aminoglycoside should be strongly
considered in those with severe cavitary disease to improve treatment outcomes,
and new CF-specific guidelines suggest that smear-positive MAC and/or cases
associated with systemic signs of illness are also indications for parenteral amino-
glycoside use [48•, 59]. Generally, intravenous (IV) amikacin is the drug of choice;
however, intramuscular streptomycin is a reasonable alternative with good efficacy
against MAC [60]. When used for MAC treatment, amikacin or streptomycin
should be administered for one to three months [48•]. Dosing of these aminogly-
cosides three times a week appears comparable to daily lower dose administration
without increasing toxicity [49, 61].
Guidelines recommend testing for macrolide resistance in the following situa-
tions: all new MAC cultures, when MAC regrows after recent eradication, or when
there is treatment failure (defined by some as failure to convert to culture negative
after 4 months of adequate therapy) [20, 59]. Of note, there is no additional
proven value in susceptibility testing for other antibiotics in the setting of new
MAC infection [20].
Despite prolonged courses of multidrug therapy, effective cure for MAC lung
disease is just under 60% in the general population (without immune suppression
or CF) [62]. There are no randomized controlled trials comparing NTM treatment
regimens in CF; therefore, knowledge regarding drug efficacy is derived from
studies in the broader population. Several studies of MAC treatment in non-CF
bronchiectasis, which included macrolide, ethambutol, and rifamycin therapy in
combinationwith IV amikacin (or streptomycin), demonstrated culture conversion
in approximately 50%of subjects at 6 to 12months [63–68]. The average time for
culture conversion was 4 months, with a wide range among the studies [63–68].
MAC recurrence rates in the non-CF population are significant despite adequate
therapy, reaching 40 % after 3 years of follow-up [20].
Although there are no controlled clinical trials regardingMAC treatment efficacy
and recurrence rates in CF, a few case series exist. Macrolide-based triple therapy
regimens (some including IV amikacin) lead to 90 % (n = 11) and 100 % (n = 5)
culture conversion rates in two separate studies, but the authors did not report on
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the timing of conversion or recurrence rates [69, 70]. Although the conversion rates
appear much higher in these studies than the non-CF bronchiectasis population,
this needs to be interpreted with caution due to the small sample size, milder CF
lung disease inmost of the cases, and the variability in treatment regimens [69, 70].
Importantly, while some individuals may never be able to achieve cure, ongoing
treatment for mycobacterial suppression and prevention of disease progression
should still be considered if the therapy is reasonably well tolerated [48•, 59].
MABSC treatment
MABSC treatment is more complex and challenging than the treatment of other
NTM species. Inducible macrolide resistance is especially problematic and
common in M. abscessus ssp. abscessus and M. abscessus ssp. bollettii infections
as they harbor the erythromycin ribosomemethyltransferase (erm41) gene [71].
The erm41 gene, when induced by macrolide exposure, leads to ribosome
methylation, which results in macrolide resistance [71]. M. abscessus ssp.
massiliense has a partial erm gene deletion, which prevents resistance by this
mechanism [48•, 53]. However, macrolide resistance can still occur in all
MABSC through other, less common mechanisms [28]. Deriving an adequate
treatment regimen is challenging as the antibiotic susceptibility profile, patient
comorbidities, and intolerances all must be considered.
The therapeutic approach is similar for all MABSC subspecies. As with other
NTM, MABSC treatment requires at least three active agents simultaneously, and
the regimen should be continued for at least 1-year post-culture conversion. Similar
to other NTM,MABSC therapy is guided but not dictated by antibiotic susceptibil-
ity [48•]. In contrast toMAC,MABSC treatment is divided into an induction phase
(usually one to three months of IV antibiotics) and a maintenance phase (contin-
ued until the end of treatment); induction duration is judged by infection severity,
treatment response, and medication side effects (but not necessarily culture con-
version) [48•]. Furthermore, IV amikacin should always be used for MABSC
management in the absence of contraindications [48•]. For the induction phase,
a combination of an oral macrolide (azithromycin 250 mg daily preferred), IV
amikacin (15 mg/kg/day in divided doses), and at least one other IV agent
(cefoxitin 200 mg/kg/day divided in three doses, tigecycline 50 mg once to twice
daily, or imipenem 1 g twice daily) is recommended [48•]. Cefoxitin is often a
starting point as it is generally accessible and relativelywell tolerated [20]. Inducible
macrolide resistance is more likely with clarithromycin, providing another reason
why azithromycin is preferred for MABSC treatment [72]. For the maintenance
phase, the oralmacrolide is continued, and parenteral antibiotics are exchanged for
nebulized amikacin (250 to 500 mg twice daily) and two to three other oral
antibiotics [48•]. Oral agents often used inMABSC treatment includeminocycline,
linezolid, clofazimine, moxifloxacin and, less often, co-trimoxazole or ethambutol
[20, 48•]. It may be difficult to predict which combination the patient will respond
to and tolerate and therefore empiric choices are often required, withmodification
based on initial response and intolerances.
There are no randomized controlled trials of MABSC therapy in the general
population or in CF; however, there is MABSC treatment outcome data in non-CF
populations from several clinical studies [48•]. In a study of 56 non-CF subjects
that compared M. abscessus ssp. massiliense and ssp. abscessus infections and treat-
ment outcomes, all individuals were treated with clarithromycin and a standard 4-
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week induction period of IV amikacin and cefoxitin followed by clarithromycin,
ciprofloxacin, and ethambutol for 24months (minimum12months post-negative
culture) [73].M. abscessus ssp.massiliense demonstrated a better treatment response
withmore sustained negative cultures compared toM. abscessus ssp. abscessus (88 vs
25%) [73]. Interestingly, there was a high rate of doxycycline and fluoroquinolone
resistance while macrolide and amikacin resistance at baseline was low in both
groups [73]. In a retrospective observational study of 157 CF patients with NTM
(where approximately half had MABSC), MABSC culture conversion occurred in
one third and 25 % died, despite treatment; the nature and success of treatment
regimens were not discussed [17].
Despite intensive treatment regimens,MABSC culture conversion and cure rates
are low in CF [17], and similar to non-CF studies [73]. Consequently, MABSC cure
is often not achievable, and while it should still be attempted, guidelines indicate
that a more realistic goal is sustained symptom reduction, radiographic response,
and/or smear negative status [20].
Treatment monitoring and side effects
Sputum cultures should be monitored every four to eight weeks until culture
conversion and less frequently thereafter [20, 48•, 59]. A CT scan of the chest is
advised at the start and end of treatment [48•]. Although not routinely recom-
mended, an interim CT scan may be useful if there is clinical worsening on
treatment (not explained by an exacerbation) or if there is a failure of culture
conversion (as cavitary disease may have developed).
In addition to repeat culturing and imaging, monitoring should include
symptom review and clinical and laboratory assessment for side effects. Medi-
cation side effects and recommended monitoring are summarized in the gen-
eral and CF-specific NTM treatment guidelines [20, 59]. Irrespective of the
regimen, monthly bloodwork for cell counts, renal, and hepatic function are
advised [20, 59]. Drug level monitoring is required for amikacin but is generally
not necessary for most other medications [20, 59].
Management of treatment failure
Treatment failure refers to an inability to attain culture conversion within a
reasonable time frame; many define this as four months; however, this defini-
tion may be too strict as some individuals may still respond but take longer to
convert their cultures [20, 59]. Regardless, non-responders or slow responders
should prompt reassessment of treatment after a few months. Possible reasons
include medication non-adherence, antibiotic resistance, suboptimal drug
levels (due to under-dosing, increased clearance, or decreased absorption), or
suboptimal drug delivery to the active site (due to biofilm formation, viscous
mucus, or cavities). In the setting of treatment failure, full antibiotic suscepti-
bility testing should be performed (irrespective of the NTM type). If susceptible,
antibiotic doses could be maximized before changing to a different regimen.
Drug level monitoring may also be useful if there are concerns about subopti-
mal medication absorption or increased clearance.
MAC treatment failure has been associated with cavity formation, smear pos-
itivity, macrolide resistance (at the start or emerging during treatment), prior MAC
treatment, poor lung function, and intolerance to treatment [22, 63–66, 68].
Macrolide resistance was as high as 15% in one study, but is lower when adequate
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triple antibiotic therapy is used [20, 48•, 63]. Although there are no CF-specific
studies, guidelines suggest using IV amikacin, changing rifampin to rifabutin, and
considering clofazimine and/or moxifloxacin for macrolide-resistant MAC [20].
Evidence from the non-CF population also suggests those with intolerance/
resistance to rifamycins, have good outcomes with clofazimine, ethambutol, and
a macrolide [74]. Finally, in the setting of cavitary or treatment refractory MAC
infections, those individuals treatedwith IV amikacin and localized surgery had the
best outcomes in non-CF bronchiectasis [20]; however, lung resection surgery is
generally avoided in CF except in extenuating circumstances [48•].
With MABSC, treatment failure is more likely to occur with non-massiliense
subspecies, macrolide-resistance, lack of surgical intervention, and four or more
positive sputum cultures [17, 72, 75, 76]. Possible options for MABSC infection
refractory to first-line therapy is exchanging the beta-lactam for IV tigecycline and
possibly adding clofazimine [77, 78•]. An in vitro susceptibility study involving 65
MABSC strains suggested that tigecyline and clofazimine had the greatest synergy
(in almost half of the isolates) when multiple antibiotic combinations were
evaluated [77]. A non-comparative open label clinical treatment trial for rapidly
growing NTM (mostly MABSC) that included 21 CF patients was recently pub-
lished [78•]. All were given IV tigecycline along with macrolides (75 %) [78•]. IV
aminoglycoside, linezolid, IV beta-lactam, and fluoroquinolones were used in 75,
60, 40, and 22 %, respectively [78•]. Overall, 75 % of CF subjects had clinical
improvement based on symptoms, CT findings, and/or sputum culture conversion
[78•]. However, the majority of subjects had nausea/vomiting and many
discontinued tigecycline prematurely [78•]. The study found that drug intolerance
was more likely with 100 vs 50 mg daily and with loading doses; they recom-
mended that prophylaxis with anti-emetics, avoidance of a loading dose, and slow
up-titration to the target dose (starting from 25 mg OD and increasing to 100 mg
ODover a fewweeks) could help improve drug tolerability [78•]. This studymarks
one of the first CF-specific studies of NTM treatment and provides evidence for
tigecycline efficacy and safety as part of MABSC therapy in this population. As with
cavitary or treatment-resistant MAC, those with severe MABSC have been reported
to have better outcomes with lung surgery [20, 76], but its role in CF is limited as
lung resection surgery is generally avoided [48•].
New therapies and future research opportunities
Newdevelopments inNTMmanagement include identificationof several potential
therapeutic targets and novel treatments. Gallium compounds appear to impair
M. abscessus ssp. abscessus growth in humanmacrophages by disrupting iron uptake
[79]. MgtC, anM. abscessus ssp. abscessus virulence factor, is induced upon entering
humanmacrophages; blocking this factor was protective against inhaledMABSC in
animal models andmay be a novel treatment target [80].M. abscessus ssp. abscessus
has also been shown to produce BlaMab, a beta-lactamase, which may partly
account for suboptimal response despite cefoxitin or imipenem use [81].
Avibactam, a beta-lactamase inhibitor, blocked BlaMab in human macrophages
and animal models, suggesting that combining this with beta-lactams may im-
prove MABSC treatment efficacy [81]. Piperinodol, which disrupts mycolic acid
transport, has fair anti-MABSC activity in human macrophages and zebrafish
models [82].
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Inhaled liposomal amikacin formaintenance treatment has also drawn interest.
In a randomized placebo controlled trial, CF subjects with NTM lung disease
refractory to standard therapy were assigned to 590 mg OD inhaled liposomal
amikacin or placebo, in addition to their standard CF treatments and ongoing
NTM therapy [75]. The group of 90 patients was stratified based on MAC (64 %)
andMABSC (36%) [83•]. At the end of the 6-month treatment period, there was a
statistically significant increase in culture negativity overall and for theMAC group.
However, there were no differences in the MABSC group vs placebo (which may
have been partly been due to the study being underpowered) [83•]. Although there
are no human clinical trials comparing free inhaled amikacin to liposomal
amikacin, mouse models showed liposomal amikacin was as effective as a higher
concentration of free amikacin against MAC [84]. These findings suggest that
liposomal amikacin might be beneficial as an adjunct in the management of
difficult to treat MAC (where criteria for IV amikacin are not met or there is a
contraindication). This formulation of amikacin was well tolerated and may be
useful in MABSC treatment (but needs to be investigated further in this context).
Moving forward, NTM treatment clinical trials are urgently needed in CF, particu-
larly the development of more effective regimens for MABSC.
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